UNIverse - Public Research Portal
Profile Photo

Dr. Frédérique Chammartin

Department of Clinical Research
Profiles & Affiliations

Projects & Collaborations

10 found
Show per page
Project cover

RETUNE

Research Project  | 7 Project Members

Tobacco smoking represents a leading health burden in the aging population of people living with HIV in Switzerland. New tools for smoking cessation like electronic cigarettes or nicotine pouches are promising to reduce the harm caused by tobacco smoking. However, high quality evidence of their effectiveness among people living with HIV and outside of explanatory randomized trials is missing. 


RETUNE is a highly pragmatic randomized trial, fully embedded in the Swiss HIV Cohort Study (SHCS), using the “Trials within Cohorts” (TwiCs) design. 

In the TwiCs design, participants are recruited within a prospective cohort study and can consent not only to regular data collection at cohort visits, but also to be randomized in future low-risk pragmatic trials (“randomization consent”). Participants are informed that only participants randomized to the intervention arm are approached and may then accept or decline the offered intervention. Participants in the intervention who accept the intervention, are asked to sign an “intervention consent”, that only covers additional data collection in this group and the safety/side-effects of the intervention – similar to a routine clinical consent (e.g. consent for a lumbar puncture in clinical care). 


RETUNE aims to assess the effectiveness of the offer of a menu including different tobacco cigarettes substitutional products (e-cigarettes, nicotine pouches, nicotine patches) to quit smoking. People with HIV in the SHCS who smoke tobacco cigarettes and who signed the randomization consent will be randomized in a 1:1 ratio to the offer of the menu or to usual care. People are included regardless of their willingness to quit smoking. The primary endpoint is tobacco abstinence after 6 months. RETUNE is a multicenter trial which will include centers in Basel, Bern, Geneva, Lausanne, St. Gallen, and Zurich. 


RETUNE is funded by the Tobacco Prevention Fund, the Novartis foundation for medical-biological research, and the Swiss National Science Foundation.



Involved partner:

Swiss HIV Cohort Study

Project cover

LoDoCA: Tolerability of Ritonavir-Boosted Lopinavir- Vs Dolutegravir-Based Antiretroviral Therapy for Children and Adolescents Living with HIV: an Open-Label Randomised Study in Lesotho, Southern Africa

Research Project  | 16 Project Members

LoDoCA is a prospective cohort study among children and adolescents with HIV in Lesotho, southern Africa who changed from an antiretroviral therapy regimen containing lopinavir to a regimen containing dolutegravir. The study compares treatment satisfaction and previously reported adverse effects of either drug, including neuropsychiatric (sleep, depression) and gastrointestinal outcomes. Sleep is a key focus, as sleep disturbance has previously been reported as an adverse effect of dolutegravir among adults. Thus, sleep is measured by actigraphy (movement-sensing devices worn by participants around their wrist from around bedtime to morning) in addition to questionnaires.